Teva reports positive Phase 2a topline for anti‑IL‑15 antibody TEV ‘408 in celiac disease, meeting primary endpoint with no new safety signals
- Treatment showed meaningful protection against gluten‑induced intestinal damage following gluten exposure in the Phase 2a study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.